Conference abstract · 24 Jan 2020
Conference abstractPublished 17 Aug 2015
Development and clinical translation of nanoliposomal chemotherapeutics
Merrimack Pharmaceuticals, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Highly stabilized sustained released liposomal formulations of chemotherapeutic drugs have been developed and currently being evaluated in the clinic. These novel drug delivery systems provide for extended circulation lifetimes, preferential distribution to sites of solid tumors, and the ability to mitigate certain dose limiting toxicities when administered as the free form of the drug. Our lead agent, nal-IRI or nanoliposomal Irinotecan (MM-398) has recently completed a successful Phase III clinical trial in gemcitabine refractory pancreatic cancer. A second ErbB2-antibody targeted immunoliposomal doxorubicin is being studied in a pivotal Phase II trial in ErbB2-overexpressing breast cancer patients. The development of these and similar drugs requires the careful optimization of a variety of parameters related to the encapsulated drug, physicochemical properties of the drug carrier system itself, drug entrapment and retention strategies, and the introduction of targeting ligands. Here we will discuss both the engineering considerations as well as the translation consideration for this promising class of drug carrier systems.
Subjects
NanotechnologyOncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 24 Jan 2020
Successful delivery of docetaxel to rat brain using experimentally developed nanoliposome: A treatment strategy for brain tumor
Conference abstract · 27 Jul 2015
Towards the development of oral vaccine delivery systems for lipid core peptide-based vaccines using novel multi-layer engineered nanoliposomes against Group A streptococcus
Conference abstract · 18 Jul 2018
NanoBindi- Unified precision therapeutic platform for translating lead candidates to early clinical assets in oncology
Conference abstract · 26 Jul 2018
Chemotherapeutic activity of ellagic acid combined with doxorubicin nanoliposomes in 4T1 breast cancer cells and NIH3T3 normal breast fibroblast cells
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectNanotechnology
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Daryl C. Drummond”
